Medtronic PLC $MDT Stock Position Increased by Signet Investment Advisory Group Inc.

Signet Investment Advisory Group Inc. boosted its position in Medtronic PLC (NYSE:MDT) by 1.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,797 shares of the medical technology company’s stock after purchasing an additional 435 shares during the quarter. Signet Investment Advisory Group Inc.’s holdings in Medtronic were worth $2,162,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. 1248 Management LLC bought a new stake in Medtronic in the 1st quarter valued at about $26,000. Columbia River Financial Group LLC bought a new stake in Medtronic in the 1st quarter valued at about $28,000. Twin Tree Management LP bought a new stake in Medtronic in the 1st quarter valued at about $29,000. Activest Wealth Management lifted its position in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares during the last quarter. Finally, Hughes Financial Services LLC bought a new stake in Medtronic in the 1st quarter valued at about $32,000. 82.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MDT has been the topic of several recent research reports. Truist Financial lifted their price objective on shares of Medtronic from $96.00 to $103.00 and gave the company a “hold” rating in a research report on Wednesday, October 15th. UBS Group boosted their price target on shares of Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 20th. BTIG Research restated a “neutral” rating on shares of Medtronic in a research report on Friday, July 11th. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research report on Thursday, August 14th. Finally, Argus boosted their price target on shares of Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.82.

Medtronic Stock Performance

Shares of MDT opened at $94.09 on Tuesday. The firm’s 50 day moving average is $94.35 and its 200-day moving average is $89.48. The stock has a market capitalization of $120.69 billion, a P/E ratio of 25.92, a P/E/G ratio of 2.47 and a beta of 0.78. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $99.37.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion for the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business’s revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. Medtronic’s payout ratio is currently 78.24%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director William R. Jellison bought 2,500 shares of the company’s stock in a transaction dated Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares of the company’s stock, valued at $461,850. This represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.